Benutzer: Gast  Login
Titel:

CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.

Dokumenttyp:
Journal Article
Autor(en):
Seitz, Stefanie; Dreyer, Tobias F; Stange, Christoph; Steiger, Katja; Bräuer, Rosalinde; Scheutz, Leandra; Multhoff, Gabriele; Weichert, Wilko; Kiechle, Marion; Magdolen, Viktor; Bronger, Holger
Abstract:
BACKGROUND: Response to immune checkpoint blockade (ICB) in ovarian cancer remains disappointing. Several studies have identified the chemokine CXCL9 as a robust prognosticator of improved survival in ovarian cancer and a characteristic of the immunoreactive subtype, which predicts ICB response. However, the function of CXCL9 in ovarian cancer has been poorly studied. METHODS: Impact of Cxcl9 overexpression in the murine ID8-Trp53-/- and ID8-Trp53-/-Brca2-/- ovarian cancer models on survival, ce...     »
Zeitschriftentitel:
Br J Cancer
Jahr:
2022
Band / Volume:
126
Heft / Issue:
10
Seitenangaben Beitrag:
1470-1480
Volltext / DOI:
doi:10.1038/s41416-022-01763-0
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/35314795
Print-ISSN:
0007-0920
TUM Einrichtung:
Institut für Allgemeine Pathologie und Pathologische Anatomie; Klinik und Poliklinik für Frauenheilkunde; Klinik und Poliklinik für RadioOnkologie und Strahlentherapie
 BibTeX